RSV

New data reveal that implementing rapid diagnostic testing for RSV reduces the rate of unnecessary antibiotic prescriptions for viral respiratory infections.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Trial data indicate that clesrovimab has a safety profile comparable to palivizumab and maintained protection against RSV-related infections.

A study found that a nirsevimab immunization program reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second.

A study shows how COVID-19 reshaped the circulation, seasonality, and coinfection patterns of respiratory viruses in children.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from January 2026.

The AAP released its 2026 childhood immunization schedule, maintaining evidence-based vaccine recommendations and expanding guidance across routine, catch-up, and risk-based care.

FDA-cleared Flowflex Plus 4-in-1 home test detects RSV, influenza A/B, and COVID-19 in adults and children as young as 6 months.

Reactions from the pediatric health care community poured in following swift changes to the US childhood vaccine schedule by the CDC.

Effective immediately, the updated US childhood vaccine schedule will reduce the number of recommended vaccines for all children to 11 diseases, down from 18.

Take a look back at the top 5 FDA approvals of 2025.

In this recap article, take a look back at some of our top stories in the infectious diseases space in 2025.

According to multiple reports, the FDA is investigating the safety of a pair of already-approved protective treatments for respiratory syncytial virus.

New US modeling study results find nirsevimab would avert the most infant RSV-LRTD events and hospitalizations compared with clesrovimab or RSVpreF maternal vaccination.

Take a quick look at everything you may have missed this month, including the top FDA approvals and latest clinical updates.

Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.